Eupraxia Pharmaceuticals (EPRX) Other Non Operating Income (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Other Non Operating Income of $2.2 million for Q1 2026, up 4265.16% year-over-year from $51362.0 in Q1 2025, and up 192.38% quarter-over-quarter from -$2.4 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Other Non Operating Income (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Other Non Operating Income for 4 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 4265.16% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at -$1.4 million (down 4905.89% YoY), while the FY2025 annual figure was -$1.6 million, down 881.37% from the prior year.
- Other Non Operating Income improved to $2.2 million in Q1 2026 per EPRX's latest filing, from -$2.4 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $2.2 million in Q1 2026 and bottomed at -$2.4 million in Q4 2025.
- Historically, Other Non Operating Income has averaged -$113486.4 across 4 years, with a median of -$25965.0 in 2023.
- Annual changes were most pronounced in 2025 — Other Non Operating Income sank 3316.09% — and 2026, when it surged 4265.16%.
- Eupraxia Pharmaceuticals' Other Non Operating Income stood at $59281.0 in 2023, then tumbled by 219.85% to -$71047.0 in 2024, then tumbled by 3316.09% to -$2.4 million in 2025, then jumped by 192.38% to $2.2 million in 2026.
- Business Quant data shows EPRX's Other Non Operating Income at $2.2 million in Q1 2026, -$2.4 million in Q4 2025, and -$508633.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.24 Mn |
| Dec 31, 2025 | -2.43 Mn |
| Sep 30, 2025 | -508,633.00 |
| Jun 30, 2025 | -733,961.00 |
| Mar 31, 2025 | 51,362.00 |
| Dec 31, 2024 | -71,047.00 |
| Sep 30, 2024 | 124,431.00 |
| Jun 30, 2024 | -75,041.00 |
| Mar 31, 2024 | -143,728.00 |
| Dec 31, 2023 | 59,281.00 |
| Sep 30, 2023 | -25,965.00 |
| Jun 30, 2023 | 9,942.00 |
| Mar 31, 2023 | 23,033.00 |